Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCLIN.L Share News (CLIN)

  • There is currently no data for CLIN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: Tullow Oil Up 6% After Reinstating Dividend

Wed, 13th Feb 2019 10:43

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Wednesday.----------FTSE 100 - WINNERS----------Smurfit Kappa, up 2.5%. The Irish paper and corrugated packaging firm raised its dividend on the back of higher annual revenue and earnings. For 2018, revenue was EUR8.95 billion, up 4.6% from EUR8.56 billion in 2017 and earnings before interest, taxes, depreciation and amortisation totalled EUR1.58 billion, versus EUR1.27 billion the year before. Consensus was for EUR1.53 billion. However, the company said it swung to a loss at the pretax level after the Venezuelan government seized its business there, amid political chaos. Smurfit's 2018 pretax loss was EUR404 million, swinging from a EUR576 million profit in 2017. On a pre-exceptional basis, Smurfit Kappa's pretax profit was EUR938 million, up 56% from EUR601 million the year before. The company declared a final dividend of 72.2 euro cents per share, bringing the total for 2018 up 11% to 97.6 cents from from 87.6 cents in 2017. Peers DS Smith and Mondi were up 4.4% and 1.5% respectively. ----------Rolls-Royce Holdings, up 2.5%. Credit Suisse raised the jet engine maker to Outperform from Neutral. ----------FTSE 100 - LOSERS----------TUI, down 3.5%. Shares in the Anglo-German travel operator were adding to their losses on Wednesday after the company reported on Tuesday a widened loss in the first quarter. Last week, TUI had warned on stagnating earnings going forward. The stock is down 28% over the past week. RELX, down 1.7%. The Anglo-Dutch information and analytics firm was cut to Hold from Buy by Deutsche Bank. ----------FTSE 250 - WINNERS----------Galliford Try, up 6.5%. The construction company and housebuilder guided for its annual results to come in at the upper end of market expectations but also reported a drop in interim revenue and profit. For the six months to the end of 2018, Galliford's revenue fell to GBP1.34 billion from GBP1.40 billion in the comparative period a year ago. Pretax profit was down 4% year-on-year to GBP53.8 million. The company cut its interim dividend by 18% to 23 pence per share from the 28p paid to shareholders a year ago. During the half, Galliford reported a GBP26 million charge related to the Aberdeen Western Peripheral Route, which was set back by the collapse of partner Carillion. Looking ahead, at a group level, the company reported an increase in total sales currently reserved, despite its current order book standing at GBP5.4 billion, lower than the same period last year at GBP5.6 billion. ----------Tullow Oil, up 5.9%. The oil and gas firm declared its first dividend since 2015 on Wednesday, as it swung to a significant annual profit. Tullow declared a dividend of 4.8 US cents per share for 2018, worth USD67 million in total. From 2019 onwards, it expects any dividends, paid twice a year, to be worth at least USD100 million. Tullow's pretax profit for 2018 was USD260.5 million, after a pretax loss in 2017 of USD285.9 million. Revenue climbed to USD1.86 billion from USD1.72 billion. In 2017, Tullow made a USD539.1 million impairment, compared to just USD18.2 million in 2018. For 2019, overall oil production is guided to be 93,000 barrels of oil a day to 101,000 barrels. With gas, the figure is estimated to be between 94,000 barrels of oil equivalent a day to 102,000 barrels. ----------Dunelm, up 3.4%. The homewares retailer said profit in the first half of its financial year jumped 24% on the back of a strong increase in like-for-like sales. For the six months to December 29, the retailer reported a pretax profit of GBP70.0 million, up from GBP56.3 million in the comparative period a year ago. Revenue, meanwhile, rose 1.2% to GBP551.8 million from GBP545.4 million. On a like-for-like basis, revenue was up 6.9% year-on-year to GBP506.7 million from GBP473.9 million. Store like-for-like sales were up 3.8% to GBP444.2 million while online surged 36% to GBP62.5 million. Dunelm upped its interim payout by 7.1%, proposing an interim dividend of 7.5 pence per share from 7.0p paid a year ago. ----------FTSE 250 - LOSERS----------Great Portland Estates, down 1.2%, Derwent London, down 1.2%. Berenberg started coverage on the property development companies with Sell ratings. ----------OTHER MAIN MARKET AND AIM - WINNERS----------Clinigen, up 17%. The pharmaceuticals firm announced the purchase of the rights to one of Novartis International's drugs. Clinigen is to paying USD210 million in cash to the Swiss firm for the rights to Proleukin in the US. Clinigen already owns the rights to the drug in the rest of the world. Proleukin is a treatment for metastatic melanoma, and metastatic renal cell carcinoma. It has the potential, Clinigen said, to become "an integral part" of cancer combination therapies, and is currently being used in around 80 active studies. Clinigen will pay an initial USD120 million, with USD60 million deferred over the next 12 months and then a further USD30 million depending on Proleukin's sales. Clinigen provided some guidance for its first half ended December. It expects adjusted earnings before interest, tax, depreciation, and amortisation to be GBP41.8 million, from GBP34.4 million a year prior. ----------Polo Resources, up 16% at 4.76 pence. Phronimos Capital said it wrote to the natural resources investor in January requesting a tender offer to return 10 to 12 pence per share to shareholders. Phronimos said funds could be sourced from a sale of some or all of Polo's "successful" investment in Hibiscus Petroleum, with the entire stake double Polo's market capitalisation. Selling one-third of the Hibiscus stake, the advisor continued, could allow Polo to buyback 20% of its shares at 12p, a significant premium to its current share price. It believes there would be widespread shareholder support for the move. Phronimos does not dispute Polo's right to "generously" pay its leadership when they help create shareholder wealth, but it noted Polo's share price has fallen 80% over the past five years with no returns whatsoever.----------OTHER MAIN MARKET AND AIM - LOSERS----------ASOS, down 4.8%. Merrill Lynch downgraded the online fashion retailer to Underperform from Neutral. ----------

More News
7 Nov 2016 16:05

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
30 Oct 2016 14:52

Sunday newspaper round-up: More 'Nissan' deals, Carney, RBS, HSBC, Capita

(ShareCast News) - Pharmaceuticals giants want the government to plug a £1bn-a-year funding gap that will be created when Britain leaves the EU, as part of a list of demands being drawn up by big business after last week's deal with Nissan. After the Japanese car maker said it would make two new mod

Read more
25 Oct 2016 08:50

Clinigen Group extends partnership with BTG

(ShareCast News) - AIM-listed pharmaceutical Clinigen Group's Idis Global Access division extended its four-year partnership with BTG, a healthcare company, to manage its critical care portfolio across the whole of Europe and new territories in Asia. The agreement now includes all of Europe and some

Read more
25 Oct 2016 06:37

Clinigen Group Extends Exclusive Supply Agreement With BTG

Read more
18 Oct 2016 08:36

Clinigen expands operations into Japan

(ShareCast News) - Clinigen Group, an AIM listed global pharmaceuticals and services company, has extended its geographical reach to Japan with the opening of a new office in Tokyo. Clinigen KK further expands the group's presence in Asia following the company's acquisition of Link healthcare in 201

Read more
18 Oct 2016 07:45

Clinigen Opens Tokyo Office To Take Foscavir Marketing Back In-House

Read more
5 Oct 2016 16:13

DIRECTOR DEALINGS SUMMARY: Clinigen Executive Slashes Shareholding

Read more
28 Sep 2016 09:43

WINNERS & LOSERS SUMMARY: UK Mail Jumps On Deutsche Post Cash Offer

Read more
22 Jul 2016 10:21

Clinigen Group issues 38k option shares

(ShareCast News) - Clinigen Group announced on Friday that it has made an application for the admission to trading on AIM of 38,308 ordinary shares of 0.1p each. The firm said the shares have been issued to satisfy the exercise of share options, and rank pari passu with the existing shares of the gr

Read more
20 Jul 2016 14:42

Clinigen revenue and profits see serious rise

(ShareCast News) - Global pharmaceutical and services company Clinigen Group posted a trading update for the year to 30 June on Wednesday, reporting an 87% improvement in revenue and a 90% increase in gross profit. The AIM-traded firm said the growth was driven primarily by acquisitions and organic

Read more
20 Jul 2016 09:47

WINNERS & LOSERS SUMMARY: Man Group Down As CEO Departs For PIMCO

Read more
20 Jul 2016 07:02

Clinigen Revenue And Profit Surge On Acquisitions, Organic Growth

Read more
13 Jul 2016 15:02

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
7 Jul 2016 15:27

Clinigen Group Issues 83,016 Shares In Option Exercise (ALLISS)

Read more
29 Jun 2016 12:20

Clinigen teams up with Horizon on RAVICTI

(ShareCast News) - Clinigen Group was celebrating on Wednesday, as its Idis Managed Access division and Nasdaq-traded Horizon Pharma initiated a Managed Access Programme in Europe for Horizon's RAVICTI oral liquid. The AIM-traded firm said RAVICTI received centralised marketing approval from the Eur

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.